Eagle Net Debt from 2010 to 2024

EGRX Stock  USD 4.76  0.01  0.21%   
Eagle Pharmaceuticals Net Debt yearly trend continues to be fairly stable with very little volatility. Net Debt is likely to outpace its year average in 2024. Net Debt is the total debt of Eagle Pharmaceuticals minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. View All Fundamentals
 
Net Debt  
First Reported
2012-09-30
Previous Quarter
54.4 M
Current Value
54.8 M
Quarterly Volatility
37.2 M
 
Yuan Drop
 
Covid
Check Eagle Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Eagle main balance sheet or income statement drivers, such as Depreciation And Amortization of 14.5 M, Interest Expense of 4.9 M or Selling General Administrative of 118.5 M, as well as many exotic indicators such as Price To Sales Ratio of 1.3, Ptb Ratio of 1.77 or Days Sales Outstanding of 129. Eagle financial statements analysis is a perfect complement when working with Eagle Pharmaceuticals Valuation or Volatility modules.
  
This module can also supplement Eagle Pharmaceuticals' financial leverage analysis and stock options assessment as well as various Eagle Pharmaceuticals Technical models . Check out the analysis of Eagle Pharmaceuticals Correlation against competitors.
For more information on how to buy Eagle Stock please use our How to Invest in Eagle Pharmaceuticals guide.

Latest Eagle Pharmaceuticals' Net Debt Growth Pattern

Below is the plot of the Net Debt of Eagle Pharmaceuticals over the last few years. It is the total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. Eagle Pharmaceuticals' Net Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Eagle Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Net Debt10 Years Trend
Pretty Stable
   Net Debt   
       Timeline  

Eagle Net Debt Regression Statistics

Arithmetic Mean(29,655,471)
Coefficient Of Variation(117.28)
Mean Deviation31,321,160
Median(22,722,000)
Standard Deviation34,780,233
Sample Variance1209.7T
Range86.2M
R-Value(0.13)
Mean Square Error1280.6T
R-Squared0.02
Significance0.64
Slope(1,013,416)
Total Sum of Squares16935.3T

Eagle Net Debt History

20246.8 M
20236.4 M
20227.1 M
2021-72.1 M
2020-66.1 M
2019-71.2 M
2018-34.4 M

Other Fundumenentals of Eagle Pharmaceuticals

Eagle Pharmaceuticals Net Debt component correlations

0.890.79-0.020.940.930.910.98-0.240.960.860.080.80.390.660.290.90.690.350.570.29-0.810.71
0.890.87-0.320.890.790.80.9-0.250.760.980.080.920.480.760.240.940.380.290.460.3-0.680.51
0.790.87-0.120.910.690.820.78-0.170.70.830.310.690.190.650.510.920.390.310.410.43-0.720.5
-0.02-0.32-0.12-0.070.090.04-0.070.170.25-0.43-0.05-0.46-0.56-0.690.48-0.110.680.390.53-0.26-0.330.47
0.940.890.91-0.070.820.930.93-0.220.870.860.250.750.330.740.430.920.550.220.420.41-0.770.58
0.930.790.690.090.820.860.88-0.230.920.730.250.710.340.490.340.810.720.570.570.43-0.840.71
0.910.80.820.040.930.860.88-0.170.90.810.340.670.310.630.390.870.620.440.470.5-0.840.64
0.980.90.78-0.070.930.880.88-0.260.910.880.00.820.450.70.250.880.60.250.490.23-0.740.64
-0.24-0.25-0.170.17-0.22-0.23-0.17-0.26-0.21-0.260.02-0.1-0.44-0.350.2-0.22-0.01-0.02-0.04-0.030.07-0.06
0.960.760.70.250.870.920.90.91-0.210.710.060.640.240.440.360.830.850.480.710.22-0.880.83
0.860.980.83-0.430.860.730.810.88-0.260.710.080.930.560.840.110.90.280.220.350.32-0.610.43
0.080.080.31-0.050.250.250.340.00.020.060.080.06-0.190.190.330.23-0.040.32-0.190.9-0.33-0.02
0.80.920.69-0.460.750.710.670.82-0.10.640.930.060.480.760.030.810.250.180.310.29-0.540.39
0.390.480.19-0.560.330.340.310.45-0.440.240.56-0.190.480.63-0.090.23-0.13-0.15-0.13-0.020.09-0.07
0.660.760.65-0.690.740.490.630.7-0.350.440.840.190.760.63-0.080.67-0.07-0.19-0.120.45-0.280.08
0.290.240.510.480.430.340.390.250.20.360.110.330.03-0.09-0.080.310.450.250.350.1-0.390.36
0.90.940.92-0.110.920.810.870.88-0.220.830.90.230.810.230.670.310.530.430.590.42-0.850.66
0.690.380.390.680.550.720.620.6-0.010.850.28-0.040.25-0.13-0.070.450.530.570.84-0.01-0.790.87
0.350.290.310.390.220.570.440.25-0.020.480.220.320.18-0.15-0.190.250.430.570.680.35-0.70.63
0.570.460.410.530.420.570.470.49-0.040.710.35-0.190.31-0.13-0.120.350.590.840.68-0.15-0.740.89
0.290.30.43-0.260.410.430.50.23-0.030.220.320.90.29-0.020.450.10.42-0.010.35-0.15-0.450.06
-0.81-0.68-0.72-0.33-0.77-0.84-0.84-0.740.07-0.88-0.61-0.33-0.540.09-0.28-0.39-0.85-0.79-0.7-0.74-0.45-0.8
0.710.510.50.470.580.710.640.64-0.060.830.43-0.020.39-0.070.080.360.660.870.630.890.06-0.8
Click cells to compare fundamentals

About Eagle Pharmaceuticals Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Eagle Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Eagle Pharmaceuticals investors use historical funamental indicators, such as Eagle Pharmaceuticals's Net Debt, to determine how well the company is positioned to perform in the future. Although Eagle Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Eagle Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Eagle Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Eagle Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Eagle Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Debt6.4 M6.8 M
Net Debt To EBITDA 0.11  0.13 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Eagle Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Eagle Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Eagle Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Eagle Pharmaceuticals Stock:
Check out the analysis of Eagle Pharmaceuticals Correlation against competitors.
For more information on how to buy Eagle Stock please use our How to Invest in Eagle Pharmaceuticals guide.
You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.

Complementary Tools for Eagle Stock analysis

When running Eagle Pharmaceuticals' price analysis, check to measure Eagle Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eagle Pharmaceuticals is operating at the current time. Most of Eagle Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eagle Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eagle Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eagle Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
FinTech Suite
Use AI to screen and filter profitable investment opportunities
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Bonds Directory
Find actively traded corporate debentures issued by US companies
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Commodity Directory
Find actively traded commodities issued by global exchanges
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Is Eagle Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eagle Pharmaceuticals. If investors know Eagle will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eagle Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.87)
Earnings Share
0.85
Revenue Per Share
19.684
Quarterly Revenue Growth
(0.13)
Return On Assets
0.0663
The market value of Eagle Pharmaceuticals is measured differently than its book value, which is the value of Eagle that is recorded on the company's balance sheet. Investors also form their own opinion of Eagle Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Eagle Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eagle Pharmaceuticals' market value can be influenced by many factors that don't directly affect Eagle Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eagle Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eagle Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eagle Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.